Vivek K. Jayaraman Sells 10,780 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS - Get Free Report) COO Vivek K. Jayaraman sold 10,780 shares of the company's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $1.55, for a total transaction of $16,709.00. Following the sale, the chief operating officer now directly owns 905,828 shares in the company, valued at $1,404,033.40. This trade represents a 1.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Cerus Stock Performance

Shares of Cerus stock traded down $0.02 on Friday, hitting $1.51. The stock had a trading volume of 1,867,261 shares, compared to its average volume of 1,505,992. Cerus Co. has a twelve month low of $1.38 and a twelve month high of $2.54. The business's 50 day moving average is $1.74 and its two-hundred day moving average is $1.79. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The stock has a market cap of $280.54 million, a price-to-earnings ratio of -13.73 and a beta of 1.56.

Cerus (NASDAQ:CERS - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The company had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. Analysts forecast that Cerus Co. will post -0.08 EPS for the current year.

Remove Ads

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Institutional Investors Weigh In On Cerus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rockport Wealth LLC bought a new position in shares of Cerus in the 4th quarter valued at $25,000. Cibc World Markets Corp acquired a new stake in Cerus in the fourth quarter valued at $26,000. R Squared Ltd acquired a new stake in Cerus in the fourth quarter valued at $29,000. Virtu Financial LLC acquired a new stake in Cerus in the fourth quarter valued at $33,000. Finally, Dark Forest Capital Management LP acquired a new stake in Cerus in the fourth quarter valued at $34,000. 78.37% of the stock is currently owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.